ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
- PMID: 30209236
- PMCID: PMC6177274
- DOI: 10.1212/WNL.0000000000006317
ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
Abstract
Objective: To elucidate the relationship between disease stage in amyotrophic lateral sclerosis (ALS), as measured with the King's Clinical Staging System, and cognitive and behavioral change, measured with the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).
Methods: A large multicenter observational cohort of 161 cross-sectional patients with ALS and 80 healthy matched controls were recruited across 3 research sites (Dublin, Edinburgh, and London). Participants were administered the ECAS and categorized into independent groups based on their King's clinical disease stage at time of testing.
Results: Significant differences were observed between patients and controls on all subtests of the ECAS except for visuospatial functioning. A significant cross-sectional effect was observed across disease stages for ALS-specific functions (executive, language, letter fluency) and ECAS total score but not for ALS-nonspecific functions (memory, visuospatial). Rates of ALS-specific impairment and behavioral change were also related to disease stage. The relationship between cognitive function and disease stage may be due to letter fluency impairment, whereas higher rates of all behavioral domains were seen in later King's stage. The presence of bulbar signs, but not site of onset, was significantly related to ALS-specific, ECAS total, and behavioral scores.
Conclusion: ALS-specific cognitive deficits and behavioral impairment are more frequent with more severe disease stage. By end-stage disease, only a small percentage of patients are free of neuropsychological impairment. The presence of bulbar symptoms exaggerates the differences observed between disease stages. These findings suggest that cognitive and behavioral change should be incorporated into ALS diagnostic criteria and should be included in future staging systems.
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
Comment in
-
It's time to stop saying "the mind is unaffected" in ALS.Neurology. 2018 Oct 9;91(15):679-681. doi: 10.1212/WNL.0000000000006303. Epub 2018 Sep 12. Neurology. 2018. PMID: 30209233 No abstract available.
-
Amyotrophic lateral sclerosis - a multisystem neurodegenerative disorder.Nat Rev Neurol. 2019 Jan;15(1):5-6. doi: 10.1038/s41582-018-0103-y. Nat Rev Neurol. 2019. PMID: 30446736 No abstract available.
-
Reader response: ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.Neurology. 2019 Jul 9;93(2):85-86. doi: 10.1212/WNL.0000000000007761. Neurology. 2019. PMID: 31285404 No abstract available.
-
Author response: ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.Neurology. 2019 Jul 9;93(2):86. doi: 10.1212/WNL.0000000000007760. Neurology. 2019. PMID: 31285405 No abstract available.
References
-
- Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617–628. - PubMed
-
- Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 2013;12:368–380. - PubMed
-
- Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012;83:102–108. - PubMed
-
- Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000;38:734–747. - PubMed
-
- Abrahams S, Goldstein LH, Simmons A, et al. Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Brain 2004;127:1507–1517. - PubMed
Publication types
MeSH terms
Grants and funding
- MR/L501529/1/MRC_/Medical Research Council/United Kingdom
- G0500289/MRC_/Medical Research Council/United Kingdom
- ALCHALABI-TALBOT/APR14/926-794/MNDA_/Motor Neurone Disease Association/United Kingdom
- MR/R024804/1/MRC_/Medical Research Council/United Kingdom
- SHAW/NOV14/985-797/MNDA_/Motor Neurone Disease Association/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous